Global spread of the hyl(Efm) colonization-virulence gene in megaplasmids of the Enterococcus faecium CC17 polyclonal subcluster.
Enterococcus faecium has increasingly been reported as a nosocomial pathogen since the early 1990s, presumptively associated with the expansion of a human-associated Enterococcus faecium polyclonal subcluster known as clonal complex 17 (CC17) that has progressively acquired different antibiotic resistance (ampicillin and vancomycin) and virulence (esp(Efm), hyl(Efm), and fms) traits. We analyzed the presence and the location of a putative glycoside hydrolase hyl(Efm) gene among E. faecium strains obtained from hospitalized patients (255 patients; outbreak, bacteremic, and/or disseminated isolates from 23 countries and five continents; 1986 to 2009) and from nonclinical origins (isolates obtained from healthy humans [25 isolates], poultry [30], swine [90], and the environment [55]; 1999 to 2007). Clonal relatedness was established by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST). Plasmid analysis included determination of content and size (S1-PFGE), transferability (filter mating), screening of Rep initiator proteins (PCR), and location of vanA, vanB, ermB, and hyl(Efm) genes (S1/I-CeuI hybridization). Most E. faecium isolates contained large plasmids (>150 kb) and showed variable contents of van, hyl(Efm), or esp(Efm). The hyl(Efm) gene was associated with megaplasmids (170 to 375 kb) of worldwide spread (ST16, ST17, and ST18) or locally predominant (ST192, ST203, ST280, and ST412) ampicillin-resistant CC17 clones collected in the five continents since the early 1990s. All but one hyl(Efm)-positive isolate belonged to the CC17 polyclonal subcluster. The presence of hyl(Efm) megaplasmids among CC17 from Europe, Australia, Asia, and Africa since at least the mid-1990s was documented. This study further demonstrates the pandemic expansion of particular CC17 clones before acquisition of vancomycin resistance and putative virulence traits and describes the presence of megaplasmids in most of the contemporary E. faecium isolates with different origins.
Freitas
Ana R
AR
Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Carretera de Colmenar, Madrid 28034, Spain.
Tedim
Ana P
AP
Novais
Carla
C
Ruiz-Garbajosa
Patricia
P
Werner
Guido
G
Laverde-Gomez
Jenny A
JA
Cantón
Rafael
R
Peixe
Luísa
L
Baquero
Fernando
F
Coque
Teresa M
TM
D000668:Ampicillin Resistance / Q000235:genetics; D000818:Animals; D001426:Bacterial Proteins / Q000235:genetics; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D004196:Disease Outbreaks; D016984:Enterococcus faecium / Q000145:classification / Q000187:drug effects / Q000235:genetics* / Q000472:pathogenicity; D004783:Environmental Microbiology; D005798:Genes, Bacterial; D006026:Glycoside Hydrolases / Q000235:genetics; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D006801:Humans; D066298:In Vitro Techniques; D017720:Molecular Epidemiology; D008969:Molecular Sequence Data; D010957:Plasmids / Q000235:genetics; D011200:Poultry; D013552:Swine; D020713:Vancomycin Resistance / Q000235:genetics; D014774:Virulence / Q000235:genetics
D001426:Bacterial Proteins; D006026:Glycoside Hydrolases
Can J Infect Dis Med Microbiol. 2008 May;19(3):233-6
19412380
J Clin Microbiol. 1995 Jan;33(1):24-7
7699051
Science. 2003 Mar 28;299(5615):2071-4
12663927
Biochem J. 2006 Oct 15;399(2):241-7
16822234
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14422-7
12381787
Curr Opin Microbiol. 2006 Oct;9(5):454-60
16880002
FEMS Microbiol Lett. 2000 Feb 15;183(2):201-7
10675584
Eur J Clin Microbiol Infect Dis. 2010 Mar;29(3):329-31
20016994
J Clin Microbiol. 2003 Dec;41(12):5742-6
14662973
Appl Environ Microbiol. 2005 Jun;71(6):3364-8
15933043
Future Microbiol. 2009 Nov;4(9):1125-35
19895216
J Infect Dis. 2003 Feb 1;187(3):508-12
12552437
J Antimicrob Chemother. 2008 Aug;62(2):279-83
18440933
Antimicrob Agents Chemother. 2005 Jul;49(7):2693-700
15980338
FEMS Immunol Med Microbiol. 2010 Mar;58(2):254-68
20015231
J Infect Dis. 2009 Feb 1;199(3):342-9
19049434
Appl Environ Microbiol. 2008 Jul;74(14):4247-55
18487397
J Hosp Infect. 2001 May;48(1):43-54
11358470
J Clin Microbiol. 2002 Jun;40(6):1963-71
12037049
Microb Drug Resist. 1995 Summer;1(2):177-83
9158753
Euro Surveill. 2008 Nov 20;13(47):
19021959
J Clin Microbiol. 1999 Jul;37(7):2383-4
10408957
Appl Environ Microbiol. 2009 Jul;75(14):4904-8
19447948
FEMS Microbiol Lett. 1994 Sep 15;122(1-2):173-9
7958769
Anal Biochem. 1995 Apr 10;226(2):235-40
7793624
Mol Microbiol. 2009 Mar;71(6):1509-22
19210622
Antimicrob Agents Chemother. 2001 Mar;45(3):905-12
11181378
J Clin Microbiol. 2005 Jan;43(1):462-3
15635016
J Clin Microbiol. 2005 May;43(5):2224-30
15872246
BMC Microbiol. 2007 Apr 10;7:28
17425779
J Clin Microbiol. 2004 Oct;42(10):4473-9
15472296
Med Mal Infect. 2007 Apr;37(4):240-1
17336014
J Infect Dis. 2009 Nov 15;200(10):1566-73
19821720
J Clin Microbiol. 1995 Jun;33(6):1520-3
7650178
Plasmid. 2009 Mar;61(2):94-109
19100285
Scand J Infect Dis. 2008;40(10):778-84
18609203
Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6874-8
8341713
Clin Microbiol Infect. 2007 Sep;13(9):893-901
17617184
Antimicrob Agents Chemother. 2009 Oct;53(10):4240-6
19667280
Infect Control Hosp Epidemiol. 2004 May;25(5):384-90
15188843
J Antimicrob Chemother. 2002 Mar;49(3):489-95
11864949
Microb Drug Resist. 1996 Fall;2(3):309-17
9158791
Appl Environ Microbiol. 2007 May;73(10):3307-19
17351100
Microb Drug Resist. 2005 Summer;11(2):178-84
15910234
Euro Surveill. 2005 Jan 27;10(1):E050127.1
16556951
J Bacteriol. 1998 Sep;180(17):4426-34
9721279
Antimicrob Agents Chemother. 2008 Mar;52(3):1001-8
18180362
J Microbiol Methods. 2010 Jan;80(1):25-43
19879906
Antimicrob Agents Chemother. 2005 Jul;49(7):3073-9
15980404